Alnylam Pharmaceuticals Inc. (ALNY)
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Kevin Fitzgerald - Executive VP, Chief Scientific Officer and Head of Early Research & Early Development Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston.
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR-CM launch has exceeded initial expectations, driving significant revenue growth and reinforcing its long-term potential in the TTR space. While KARDIA-3 results for zilebesiran were mixed, the drug still holds multibillion-dollar potential, and Alnylam's pipeline remains deep and promising.
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Poulton - CFO & Executive VP Pushkal P.
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam's recent performance highlights the company's strong position in the competitive landscape.
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.56 per share a year ago.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
